Key points from article :
Causaly has raised $60 million in Series B funding to accelerate its AI-powered preclinical discovery efforts.
Developed a unique AI platform that serves as a catalyst for life sciences research organizations.
By reshaping the way data is discovered, analyzed and applied in drug discovery and development, Causaly aims to expedite the journey from laboratory insights to the launch of life-changing therapies.
Supports various complex knowledge workflows and has gained significant traction, with 12 of the top 20 pharmaceutical companies now using Causaly’s services.
Enabled a 10x increase in productivity, make novel discoveries, and experience higher success rates in preclinical programs.
New funding will be used to further enhance the company’s product and expand its commercial relationships.
To facilitate breakthrough innovations, mainly for complex and unresolved diseases.
“Knowledge is the lifeblood of research organizations, and we aim to make it discoverable, working with our customers to make sense of their scientific data and apply insights to enable evidence-driven decisions,” - Yiannis Kiachopoulos, CEO of Causaly.
